Rapid, Precise and Child-Centred Recent Advances in Diagnosing Respiratory Infections

Respiratory infectious diseases remain a leading cause of morbidity and mortality among children worldwide, demanding continual innovation in diagnostic approaches. Recent years have witnessed remarkable progress, fundamentally reshaping the landscape of pediatric respiratory diagnostics. What once required culture plates and empiric antibiotics can now be resolved, often during the first clinical encounter, by molecular cartridges, host-response assays and image-interpreting algorithms. These innovations share three imperatives: speed, precision and equity. The COVID-19 pandemic accelerated the adoption of molecular diagnostics and digital health solutions, highlighting the need for scalable testing infrastructure and robust surveillance systems in pediatric care. Molecular Diagnostics: Speed and Precision Multiplex polymerase chain reaction (PCR) panels can detect within hours a wide array of respiratory pathogens, both viral and bacterial, from a single specimen. Contemporary cartridges amplify 20–30 viral and bacterial targets from a single nasopharyngeal swab within shortest possible time (2 h), and curbing unnecessary isolation and imaging. Their high sensitivity and specificity, when embedded in stewardship protocols, have reduced empirical antibiotic use and hospital length-of-stay, particularly in infants with bronchiolitis.[1] Point-of-care molecular testing using rapid, user-friendly platforms now provide bedside results for pathogens such as influenza, RSV, and SARS-CoV-2 in <1 h. This advancement supports timely clinical decisions, especially in emergency and outpatient settings. Next-Generation Sequencing (NGS) and Metagenomics NGS allows for comprehensive pathogen identification, including rare or novel organisms, and can detect multiple pathogens simultaneously. Metagenomic sequencing also offers insights into antimicrobial resistance, though challenges with cost and data interpretation persist. CRISPR-Cas platforms (e.g., SHERLOCK and DETECTR) combine isothermal amplification with lateral-flow or Smartphone fluorescence, providing influenza, RSV or SARS-CoV-2 results in 15–30 min at costs approaching rapid antigen kits.[2] Pilot clinical trials in children report ≥95% concordance with PCR, suggesting regulatory approval in near future. Host-transcriptomic signatures now address the perennial “virus versus bacteria” dilemma. A five-gene whole-blood panel recently distinguished viral from bacterial pneumonia with 92% accuracy in children across three continents,[3,4] while an eight-gene signature correctly identified Mycoplasma pneumoniae infection despite negative cultures.[5] Cartridge integration could transform triage decisions, especially in resource-constrained settings where pathogen panels are unaffordable. For critically ill children in intensive care unit, an “unbiased metagenomic NGS (mNGS)” of tracheal aspirate can detect elusive pathogens (e.g., mycobacteria, emerging coronaviruses, and fungi) within 24 h. Studies have shown their beneficial role in changing the antimicrobial management in severe pneumonia and ventilator-associated infections.[5] Parallel data have confirmed superior sensitivity over culture for refractory pneumonias.[6] Artificial Intelligence and Digital Tools Artificial intelligence (AI) and machine learning are being incorporated into diagnostic workflows, assisting in the interpretation of imaging, clinical data, and laboratory results. Early evidence suggests these tools can improve diagnostic accuracy and efficiency, particularly in resource-limited settings. Complementing chest x-rays, AI and point-of-care lung ultrasound offer a radiation-free alternative with pooled sensitivity and specificity of 96% and 93%, respectively, for community-acquired pneumonia.[7] Advances in Sample Collection Non-invasive sampling techniques such as nasopharyngeal swabs and saliva-based tests have improved patient comfort and compliance. Recent studies demonstrate that these methods yield diagnostic results comparable to more invasive procedures, making them especially suitable for pediatric populations. Beyond swabs and scans, “breathomics (the analysis of volatile organic compounds in exhaled air)” promises a completely non-invasive screen. Initial data show discriminative breath signatures for RSV and rhinovirus, and expanding metabolomic libraries are refining disease-specific fingerprints in children.[8,9] Implementation Challenges Up-front costs for multiplex or mNGS assays can exceed laboratory budgets; CRISPR disposables require stable supply chains; and AI radiograph tools demand rigorous local validation to avoid drift. Most importantly, rapid answers must translate into rapid action: diagnostics should be hard-wired into stewardship, vaccination and isolation protocols, not bolted on as novelty tests. Where Next? The integration of molecular diagnostics, NGS, non-invasive sampling, host biomarkers, and AI-driven tools could transform the diagnosis of respiratory infectious diseases in children. Integrated platforms that merge pathogen detection, host-response and clinical decision support onto a single point-of-care device are already in pediatric feasibility studies. As these converge, pediatric pulmonologists must champion equitable reimbursement models, advocate for low-resource adaptations, and ensure diverse child populations are represented in training datasets. Culture plates will retain value for phenotypic susceptibility and surveillance, but their monopoly on initial decision-making has ended. The future clinic will begin, and frequently complete the precision therapy during the child’s very first encounter. Continued research, equitable access, and clinician education will be essential to ensure these innovations benefit children globally. Author contribution PC conceived the idea, reviewed the literature, drafted the manuscript, and submitted for publication. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.